Research Progress of Covalent Inhibitors

doi:10.6023/cjoc201804018

Chin. J. Org. Chem. ›› 2018, Vol. 38 ›› Issue (9): 2296-2306.DOI: 10.6023/cjoc201804018 Previous Articles Next Articles

Special Issue: 合成科学

Reviews

共价抑制剂的研究进展

董浩然^a, 苏比丁·塔依尔^a, 王鑫^a, 雷晓光^a,b

a 北京大学化学与分子工程学院化学生物学系北京 100871;
b 北大-清华生命科学研究中心北京 100871

收稿日期:2018-04-10 修回日期:2018-06-19 发布日期:2018-07-24
通讯作者: 雷晓光 E-mail:xglei@pku.edu.cn
基金资助:
国家重点研发计划（No.2017YFA0505200）、国家重点基础研究发展（973计划，No.2015CB856200）、国家自然科学基金（Nos.21472010，21521003，21561142002，21625201）资助项目.

Research Progress of Covalent Inhibitors

Dong Haoran^a, Subiding Tayier^a, Wang Xin^a, Lei Xiaoguang^a,b

a Department of Chemical Biology, College of Chemistry and Molecular Engineering, Peking University, Beijing 100871;
b Peking-Tsinghua Center for Life Sciences, Beijing 100871

Received:2018-04-10 Revised:2018-06-19 Published:2018-07-24
Contact: 10.6023/cjoc201804018 E-mail:xglei@pku.edu.cn
Supported by:
Project supported by the National Key Research and Development Program of China (No. 2017YFA0505200), the National Key Fundamental Research and Development of China (973 Program, No. 2015CB856200), the National Natural Science Foundation of China (Nos. 21472010, 21521003, 21561142002, 21625201).

The development of covalent inhibitors plays a major role in recent drug discovery due to their potential excellent pharmacokinetics. Covalent inhibitors are small organic molecules which interact with specific target proteins and form a covalent bond, resulting an alteration of the protein conformation and subsequently inhibit the protein activity. The modifications of proteins by covalent inhibitors are generally irreversible with some exceptions. In this review, the commercial covalent inhibitors that interact with proteins via Michael additions, nucleophilic substitution, or disulfide linkage are reviewed. The discussion on various types of warheads in covalent inhibitors could inspire future rational drug design.

Key words: covalent inhibitors, warheads, drug design

Cite this article

Dong Haoran, Subiding Tayier, Wang Xin, Lei Xiaoguang. Research Progress of Covalent Inhibitors[J]. Chin. J. Org. Chem., 2018, 38(9): 2296-2306.

Export EndNote|Reference Manager|ProCite|BibTeX|RefWorks

share this article

References

[1] Zhang, Y. K.; Lei, J. P.; Xie, D. Q. J. Am. Chem. Soc. 2015, 137, 70.
[2] Andrieu, J. P.; Guilmi, A. M. D.; Mouz, N.; Hoskins, J.; Jaskunas, S. R.; Gagnon, J.; Dideberg, O.; Vernet, T. J. Bacteriol. 1998, 180, 5652.
[3] Aronson, J. K. Meyler's Side Effects of Drugs, Elsevier Science, Amsterdam, 2016, p. 382.
[4] Drahl, C.; Cravatt, B. F.; Sorensen, E. J. Angew. Chem. Int. Ed. 2005, 44, 5788.
[5] Lu, L.; Michael, M.; Gu, Z. L.; Zhang, W. P. Sci. Rep. 2015, 5, 8783.
[6] Clement, L. L.; Tsakos, M.; Schaffert, E. S.; Scavenius, C.; Enghild, J. J.; Poulsen, T. B. Chem. Commun. 2015, 51, 12427.
[7] Uesugi, S.; Fujisawa, N.; Yoshida, J.; Watanabe, M.; Dan, S.; Yamori, T.; Shiono, Y.; Kimura, K. J. Antibiot. 2016, 69, 133.
[8] Albrecht, A.; Albrecht, L.; Janecki, T. Eur. J. Org. Chem. 2011, 2011, 2747.
[9] (a) Walker, E. H.; Pacold, M. E.; Perisic, O. Mol. Cell. 2000, 6, 909.
(b) Sorensen, E. J.; Drahl, C.; Cravatt, B. F. Angew. Chem., Int. Ed. 2005, 44, 5788.
[10] Bauman, J. E.; Jimeno, A.; Weissman, C.; Adkins, D.; Schnadig, I.; Beauregard, P.; Bowles, D. W.; Spira, A.; Levy, B.; Seetharamu, N.; Hausman, D.; Walker, L.; Rudin, C. M.; Shirai, K. Oral Oncol. 2015, 51, 383.
[11] Jones, J. B.; Middleton, H. W. Can. J. Chem. 1970, 48, 3819.
[12] Csuk, R.; Schwarz, S.; Siewert, B.; Kluge, R.; Strohl, D. Arch. Pharm. 2012, 345, 215.
[13] (a) Lei, X. G.; Yu, X. L.; Li, C. Org. Lett. 2010, 12, 4284.
(b) Lei, X. G.; Dong, T.; Li, C.; Wang, X.; Dian, L. Y.; Zhang, X. G.; Li. L.; Chen, S.; Cao, R.; Li, L.; Huang, N.; He, S. D. Nat. Commum. 2015, 6, 6522.
[14] Wei, L.; Wu, J.; Li, G.; Shi, N. Curr. Pharm. Des. 2012, 18, 1186.
[15] Díez-Dacal, B.; Perez-Sala, D. Cancer Lett. 2012, 320, 150.
[16] Grill, S. P.; Leung, C. H.; Lam, W.; Han, Q. B.; Sun, H. D.; Cheng, Y. C. Mol. Pharmacol. 2006, 70, 1946.
[17] Tanasova, M.; Sturla, S. J. Chem. Rev. 2012, 112, 3578.
[18] Cross, D. A. E.; Ashton, S. E.; Ghioghiu, S.; Eberlein, C.; Nebhan, C. A.; Spitzler, P. J.; Orme, J. P.; Finlay, M. R. V.; Ward, R. A.; Mellor, M. J.; Hughes, G.; Rahi, A.; Jacobs, V. N.; Brewer, M. R.; Mireille, E.; Sun, J.; Jin, H.; Ballard, P.; Al-Kadhimi, K.; Rowlinson, R.; Klinowska, T.; Richmond, G. H. P.; Cantarini, M.; Kim, D. W.; Ranson, M. R.; Pao, W. Cancer Discovery 2014, 4, 1046.
[19] Jackson, P. A.; Widen, J. C.; Harki, D. A.; Brummond, K. M. J. Med. Chem. 2017, 60, 839.
[20] Ward, R. A.; Anderton, M. J.; Ashton, S.; Bethel, P. A.; Box, M.; Butterworth, S. J. Med. Chem. 2013, 56, 7025.
[21] Zhou, W. J.; Ercan, D.; Chen, L.; Yun, C. H.; Li, D. N.; Capelletti, M.; Cortot, A. B.; Chirieac, L.; Iacob, R. E.; Padera, R.; Engen, J. R.; Wong, K. K.; Eck, M. J.; Gray, N. S.; Janne, P. A. Nature 2009, 462, 1070.
[22] Walter, A. O.; Sjin, R. T.; Haringsma, H. J.; Ohashi, K.; Sun, J.; Lee, K.; Dubrovskiy, A.; Labenski, M.; Zhu, Z. D.; Wang, Z. G.; Sheets, M.; St Martin, T.; Karp, R.; van Kalken, D.; Chaturvedi, P.; Niu, D. Q.; Nacht, M.; Petter, R. C.; Westlin, W.; Lin, K.; Jaw-Tsai, S.; Raponi, M.; van Dyke, T.; Etter, J.; Weaver, Z.; Pao, W.; Singh, J.; Simmons, A. D.; Harding, T. C.; Allen, A. Cancer Discovery 2013, 3, 1404.
[23] Campo, E.; Rule, S. Blood 2015, 125, 48.
[24] Wu, J. J.; Zhang, M. Z.; Liu, D. L. J. Hematol. Oncol. 2016, 9, 21.
[25] Barf, T.; Covey, T.; Izumi, R.; van der Kar, B.; Gulrajani, M.; van Lith, B.; van Hoek, M.; de Zwart, E.; Mittag, D.; Demont, D.; Verkaik, S.; Krantz, F.; Pearson, P. G.; Ulrich, R.; Kaptein, A. J. Pharmacol. Exp. Ther. 2017, 363, 240.
[26] Byrd, J. C.; Harrington, B.; O'Brien, S.; Jones, J. A.; Schuh, A.; Devereux, S.; Chaves, J.; Wierda, W. G.; Awan, F. T.; Brown, J. R.; Hillmen, P.; Stephens, D. M.; Ghia, P.; Barrientos, J. C.; Pagel, J. M.; Woyach, J.; Johnson, D.; Huang, J.; Wang, X.; Kaptein, A.; Lannutti, B. J.; Covey, T.; Fardis, M.; McGreivy, J.; Hamdy, A.; Rothbaum, W.; Izumi, R.; Diacovo, T. G.; Jojnson, A. J.; Furman, R. R. New. Engl. J. Med. 2016, 374, 323.
[27] Patel, V.; Balakrishnan, K.; Bibikova, E.; Ayres, M.; Keating, M. J.; Wierda, W. G.; Gandhi, V. Clin. Cancer Res. 2017, 23, 3734.
[28] Owens, T. D.; Yan, L. Compr. Med. Chem. Ⅲ 2017, 76.
[29] Meschini, E.; Mora-Vidal, R.; Martin, M. P.; Anscombe, E.; Staunton, D.; Geitmann, M.; Danielson, U. H.; Stanley, W. A.; Wang, L. Z.; Reuillon, T.; Golding, B. T.; Cano, C.; Newell, D. R.; Nobel, M. E. M.; Wedge, S. R.; Endicott, J. A.; Griffin, R. J. Chem. Biol. 2015, 22, 1159.
[30] Larraufie, M. H.; Yang, W. S.; Jiang, E.; Thomas, A. G.; Slusher, B. S.; Stockwell, B. R. Bioorg. Med. Chem. Lett. 2015, 25, 4787.
[31] Steinkopf, W. J. Prakt. Chem. 1927, 117, 1.
[32] Gold, A. M.; Fahrney, D. J. Am. Chem. Soc. 1963, 85, 997.
[33] Narayanan, A.; Jones, L. H. Chem. Sci. 2015, 6, 2650.
[34] Dong, J. J.; Krasnova, L.; Finn, M. G.; Sharpless, K. B. Angew. Chem., Int. Ed. 2014, 53, 9430.
[35] Moss, D. E.; Berlanga, P.; Hagan, M. M.; Sandoval, H. Alzheimer Dis. Assoc. Disord. 1999, 13, 20.
[36] Corbett, T. H.; Leopold, W. R.; Dykes, D. J.; Roberts, B. J.; Griswold, D. P.; Schabel, F. M. Cancer Res. 1982, 42, 1707.
[37] Kumar, A. A.; Mangum, J. H.; Blankenship, D. T.; Freisheim, J. H. J. Biol. Chem. 1981, 256, 8970.
[38] Baker, B. R.; Wood, W. F. J. Med. Chem. 1969, 12, 214.
[39] Baker, B. R.; Hurlbut, J. A. J. Med. Chem. 1969, 12, 221.
[40] Baker, B. R.; Wood, W. F. J. Med. Chem. 1969, 12, 216.
[41] Karanian, D. A.; Brown, Q. B.; Makriyannis, A.; Kosten, T. A.; Bahr, B. A. J. Neurosci. 2005, 25, 7813.
[42] Kokotos, G.; Kotsovolou, S.; Constantinou-Kokotou, V.; Wu, G. S.; Olivecrona, G. Bioorg. Med. Chem. Lett. 2000, 10, 2803.
[43] Brummond, K. M.; Jackson, P. A.; Widen, J. C.; Harki, D. A. J. Med. Chem. 2017, 60, 839.
[44] Gushwa, N. N.; Kang, S. M.; Chen, J.; Taunton, J. J. Am. Chem. Soc. 2012, 134, 20214.
[45] Potashman, M. H.; Duggan, M. E. J. Med. Chem. 2009, 52, 1231.
[46] Fellenius, E.; Berglindh, T.; Sachs, G.; Olbe, L.; Elander, B.; Sjcstrand, S. E.; Wallmark, B. Nature 1981, 290, 159.
[47] Gonzμlez-Bello, C. Chem. Med. Chem. 2016, 11, 22.
[48] Andersson, T.; Rohss, K.; Bredberg, E.; Hassan-Alin, M. Aliment. Pharmacol. Ther. 2001, 15, 1563.
[49] Baillie, T. A. Angew. Chem., Int. Ed. 2016, 55, 13408.
[50] Gonzalez-Bello, C. Chem. Med. Chem. 2015, 11, 22.
[51] Baker, W. L.; White, C. M. Am. J. Cardiovasc. Drugs 2009, 9, 213.
[52] Wiviott, S. D.; Braunwald, E.; McCabe, C. H.; Montalescot, G.; Ruzyllo, W.; Gottlieb, S.; Neumann, F.; Ardissino, D.; De Servi, S.; Murphy, S. A.; Riesmeyer, J.; Weerakkody, G.; Gibson, C. M.; Antman, E. M. N. Engl. J. Med. 2007, 357, 2001.
[53] John, J.; Koshy, S. J. Am. Board Fam. Med. 2012, 25, 343.
[54] Njoroge, F. G.; Chen, X. X.; Shih, N. Y.; Piwinski, J. J. Acc. Chem. Res. 2008, 41, 50.
[55] Taunton, J.; Serafimova, I. M.; Pufall, M. A.; Krishnan, S.; Duda, K.; Cohen, M. S.; maglathlin, R. L.; McFarlan, J. M.; Miller, R. M.; Frodin, M. Nat. Chem. Biol. 2012, 5, 471.
[56] Moitessier, N.; De Cesco, S.; Kurian, J.; Dufresne, C.; Mit-termaier, A. K. Eur. J. Med. Chem. 2017, 138, 96.
[57] Bradshaw, J. W.; McFarland, J. M.; Paavilainen, V. O.; Bisconte, A.; Tam, D.; Phan, V. T.; Romanov, S.; Finkle, D.; Shu, J.; Patel, V.; Ton, T.; Li, X. Y.; Loughhead, D. G.; Nunn, P. A.; Karr, D. E.; Gerritsen, M. E.; Funk, J. O.; Owen, T. D.; Verner, E.; Brameld, K. A.; Hill, R. J.; Goldstein, D. M.; Taunton, J. Nat. Chem. Biol. 2015, 7, 525.
[58] Liu, Q. S.; Sabnis, Y.; Zhao, Z.; Zhang, T. H.; Buhrlage, S. J.; Jones, L. H.; Gray, N. S. Chem. Biol. 2013, 20, 146.

共价抑制剂的研究进展

Research Progress of Covalent Inhibitors

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 9

Recommended Articles

Metrics

Comments

[1]	Yumei Zhong, Xiaoying Zou, Xiaoya Zhuo, Yihan Wang, Jiayi Shen, Lüyin Zheng, Wei Guo. Design, Synthesis and in vitro Anti-Cancer Activity of Novel Ethyl 4-Oxo-2-iminothiazolidin-5-ylidene Acetates [J]. Chinese Journal of Organic Chemistry, 2023, 43(4): 1452-1461.
[2]	Zhang Chao, Liu Zhijun, Li Yanbing, He Yepu, Lin Xiaohong, Chen Heru. Environment-Friendly Synthesis of Targeted Anticancer Drug N-(N'-Carbobenzoxyglycylprolyl)procarbazine (Z-GP-Pcb) and the Evaluation of Its Activity to Penetrate Blood-Brain Barrier [J]. Chinese Journal of Organic Chemistry, 2020, 40(2): 536-540.
[3]	Zhang Xinyi, Yuan Sheng, Zhao Jiaqiang, Zhang Lei, Zhang Chao, Wang Rikang, Chen Heru. Design Synthesis of Gardenamide A/Tacrine Hybrids and Their Protection against 6-Hydroxydopamine-Induced Insults in PC12 Cells [J]. Chin. J. Org. Chem., 2017, 37(4): 873-880.
[4]	Zhao Fei, Wang Jiang, Ding Xiao, Shu Shuangjie, Liu Hong. Application of Sulfonyl in Drug Design [J]. Chin. J. Org. Chem., 2016, 36(3): 490-501.
[5]	Zhang Ji, Jin Chuanfei, Zhang Yingjun. Recent Advances in Research and Development of Fluorinated Drugs and New Methods for Fluorination, Mono-, Di-and Tri-fluoromethylation [J]. Chin. J. Org. Chem., 2014, 34(4): 662-680.
[6]	Wang Jiang, Liu Hong. Application of Nitrile in Drug Design [J]. Chin. J. Org. Chem., 2012, 32(9): 1643-1652.
[7]	WANG Jiang, LIU Hong. Fluorine in Medicinal Chemistry [J]. Chin. J. Org. Chem., 2011, 31(11): 1785-1798.
[8]	MIN Jian, WANG Peng-Cheng, DONG Chun-E, ZHOU Hai-Bing. Progress in Small Molecular Inhibitors of Protein-Protein Interactions [J]. Chin. J. Org. Chem., 2010, 30(11): 1778-1789.
[9]	LIU Zheng-Xiao, ZHAO Wei-Guang, LI Zheng-Ming. Dynamic Combinatorial Chemistry and Its Applications in Drug Design [J]. Chinese Journal of Organic Chemistry, 2004, 24(1): 1-6.